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ABSTRACT: The clinical value of current and future nano-
medicines can be improved by introducing patient selection
strategies based on noninvasive sensitive whole-body imaging
techniques such as positron emission tomography (PET). Thus, a
broad method to radiolabel and track preformed nanomedicines
such as liposomal drugs with PET radionuclides will have a wide
impact in nanomedicine. Here, we introduce a simple and eﬃcient
PET radiolabeling method that exploits the metal-chelating proper-
ties of certain drugs (e.g., bisphosphonates such as alendronate and
anthracyclines such as doxorubicin) and widely used ionophores to
achieve excellent radiolabeling yields, purities, and stabilities with
89Zr, 52Mn, and 64Cu, and without the requirement of modiﬁcation
of the nanomedicine components. In a model of metastatic breast
cancer, we demonstrate that this technique allows quantiﬁcation of the biodistribution of a radiolabeled stealth liposomal
nanomedicine containing alendronate that shows high uptake in primary tumors and metastatic organs. The versatility,
eﬃciency, simplicity, and GMP compatibility of this method may enable submicrodosing imaging studies of liposomal
nanomedicines containing chelating drugs in humans and may have clinical impact by facilitating the introduction of
image-guided therapeutic strategies in current and future nanomedicine clinical studies.
KEYWORDS: nanomedicine, PET imaging, tumor, metastasis, drug delivery, liposomes
Despite the potential advantages of nanomedicines toimprove drug delivery,1 they have so far only made amodest clinical impact to date with applications in a
limited set of indications and without major improvements over
conventional chemotherapies.2 Their eﬀect in preventing or
diminishing potential toxic side eﬀects of the encapsulated drug
payloads has been more pronounced, due to diﬀerential drug
release in target and nontarget sites. For example, Doxil/
Caelyxa PEGylated (stealth) liposome containing doxor-
ubicinhas shown equal or slightly superior eﬃcacy to
conventional chemotherapy in AIDS-related Kaposi’s sarcoma,
ovarian cancer, breast cancer, and multiple myeloma while,
importantly, abolishing or greatly attenuating the often dose-
limiting cardiotoxicity of an equivalent amount of non-
encapsulated doxorubicin.3 Hence, most nanomedicines with
clinical approval today are used as second-line treatments or as
part of combination therapies with the major advantage of
lower side eﬀects.
In addition to the diﬃculties of delivering drug nanocarriers
to speciﬁc tissues in vivo,4,5 a major factor that contributes to
the failure of nanomedicines to show their full potential in the
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clinic is patient and disease heterogeneity,6 as recently
demonstrated in cancer patients. Thus, PEGylated liposomes,
known to accumulate in solid tumors due to the enhanced
permeation and retention (EPR) eﬀect, did not accumulate in
tumors at the same level neither in patients with the same nor
in patients with diﬀerent cancers.7 This highlights the clinical
need to assess which patient group is most likely to accumulate
high amounts of the nanomedicine of interest and hence
beneﬁt maximally from nanomedicinal treatment and to do so
as early as possible in the treatment regimen. Such a
personalized medicine approach may allow nanomedicines,
alone or in combination with other therapies, to demonstrate
their full clinical potential.6,8−10
Of the several clinically available noninvasive imaging
techniques that would allow such a treatment response
prediction tool in the context of nanomedicines, positron
emission tomography (PET) is the only one that allows
quantitative analysis of biodistribution with exquisite sensitivity
(signal/background ratios) and adequate spatial/temporal
resolution at the whole-body level. Radiolabeling of liposomal
nanomedicines with radionuclides detectable by other nuclear
imaging techniques such as single-photon emission computed
tomography (SPECT) or planar imaging has been successfully
used to study their biodistribution in preclinical and clinical
studies.8,9,11 SPECT imaging, however, suﬀers from lower
sensitivity and temporal/spatial resolution than PET. Radio-
labeling of liposomal drugs with PET isotopes has been
explored to a much lesser extent by using radiolabeled lipids or
by introduction of exogenous chelators in the intraliposomal
space/phospholipid bilayer.12−23 Both strategies can be useful
in the preclinical setting but represent a signiﬁcant translational
barrier for clinical imaging, as liposome modiﬁcation can lead to
changes in biodistribution, regulatory barriers, and the
requirement of customized liposome manufacture. To minimize
this barrier, an ideal radiolabeling method would work on
preformed liposomal nanomedicines (without changes in the
manufacture) containing approved components and using
clinical radiolabeling reagents and methods. In addition,
radiochemical purities of >95% (as required for most
radiopharmaceuticals) should be achieved and ideally from
high radiolabeling yield reactions (>95%), hence avoiding the
requirement for puriﬁcation steps. A move in this direction was
recently made by Abou et al. by exploiting the oxygen-rich
nature of the phospholipid hydrophilic heads and the
oxophilicity of 89Zr but suﬀering from modest stability in
biological media.24 Moreover, high speciﬁc activities (i.e.,
radioactivity per amount of nanomedicine) should be achieved,
allowing the radiolabeling of subtherapeutic amounts of
Figure 1. Liposomal nanomedicine PET radiolabeling method. (A) Chemical structure of drugs explored in this study, with metal-binding
motifs highlighted in color. (B) Radiometal−ionophore complexes used to radiolabel liposomal nanomedicines: 8HQ = 8-hydroquinoline;
2HQ = 2-hydroxyquinoline. (C) Schematic representation of the liposome radiolabeling method. Top: Incubation of empty liposomes,
lacking encapsulated drug, do not radiolabel after incubating with the radiometal−ionophore complex in PBS or saline at 50 °C for 30 min.
Bottom: Drug-loaded liposomes eﬃciently radiolabel under the same conditions. (D) Radiolabeling yields of diﬀerent liposomes with
diﬀerent PET radiometals and at diﬀerent liposome concentrations (n = 3). Note the x-axis is in log scale. (E) Serum stabilities after
incubating liposomes in human serum at 37 °C for up to 72 h (89Zr, 52Mn) or 48 h (64Cu) (n = 3).
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nanomedicine and hence microdosing PET studies (deﬁned as
1% of the therapeutic dose).
We noticed that many drugs of clinical interest in
nanomedicine have metal-binding motifs (Figure 1A and
Figure S1). Hence, we hypothesized that preformed liposomal
nanomedicines containing such drugs could be eﬃciently
radiolabeled with metallic PET isotopes such as 89Zr (t1/2 =
78.4 h), 52Mn (t1/2 = 134.2 h), and
64Cu (t1/2 = 12.7 h), by
using well-established metal ionophores (Figure 1B,C).
Furthermore, the high concentration of metal-binding drug
molecules inside the liposome and the protective eﬀect of the
phospholipid bilayer from plasma protein transchelation should
result in high radiolabeling yields, speciﬁc activities, and
stabilities compared to previously reported methods. This
strategy would allow the simple radiolabeling and PET imaging
of many current and future liposomal nanomedicines and
facilitate the introduction of treatment response prediction
tools based on PET in the clinical setting. Here, we
demonstrate and discuss the feasibility and eﬀectiveness of
this method, as well as its advantages and limitations, and show
its utility for detecting and quantifying the biodistribution of a
liposomal nanomedicine containing an aminobisphosphonate in
vivo.
RESULTS
Liposomal Drug PET Radiolabeling Method Develop-
ment. Radiolabeling development was performed using
radiometal−ionophore complexes and a PEGylated liposome
loaded with an aminobisphosphonate, alendronate (ALD,
Figure 1A). This liposomal formulation is referred to as PLA.
An aminobisphosphonate was selected as the radionuclide-
binding drug of choice to develop this method for two reasons:
(i) known ability to act as metal chelators to form inert
coordination complexes with zirconium,25 copper,26 and
manganese;26 and (ii) demonstrated anticancer activity and
γ−δ T-cell immunotherapy sensitizing properties.27−29 An
ionophore was required to transport the radionuclide through
the PEGylated lipid bilayer. We selected hydroxyquinoline
(8HQ) and 2-hydroxyquinoline (2HQ) for their known
properties to transport metal ions across lipid bilayers.14,30,31
The eﬀects of temperature and incubation times were studied.
Excellent radiolabeling yields (RLYs) and purities of >95%
were obtained with 89Zr(8HQ)4,
52Mn(8HQ)2, and
64Cu-
(2HQ)2 (Figure 1B), after being incubated with PLA in PBS at
50 °C with shaking for 30 min (Figure 1C). These reaction
conditions did not change the physicochemical properties of
the liposomes, as assessed by dynamic light scattering (DLS)
and ζ-potential measurements, pre- and post-incubation (Table
S1). Lower temperatures and incubation times resulted in lower
RLYs.
Radiolabeling Depends on the Presence and Con-
centration of the Encapsulated Drug, Its Counterion,
and the Radionuclide Used. To probe the versatility of this
radiolabeling method, we tested it with three positron-emitting
metals (89Zr, 52Mn, and 64Cu) and ﬁve diﬀerent PEGylated
liposomes. These liposomes had identical/near-identical
physicochemical properties (phospholipid composition, hydro-
dynamic size, and ζ-potential) but contained diﬀerent drugs/
combination of drugs (ALD (PLA); ALD + doxorubicin
(PLAD; 4 μmol/mL ALD/3 μmol/mL doxorubicin); sodium
salt of ALD (PLA-Na); doxorubicin (Doxil), or empty
(PLACEBO)). The involvement of the encapsulated drug in
the radiolabeling process was conﬁrmed by attempting the
radiolabeling of PLACEBO liposomes. Hence, using the above-
mentioned optimized conditions, PLACEBO liposomes were
not labeled (RLYs < 5%) with any of the radionuclides
explored in this work (Figure 1C). Drug-loaded liposomes,
however, were radiolabeled in a drug-concentration-dependent
manner (Figure 1D and Table S4). RLYs obtained with 89Zr
and 52Mn were very high over a broader drug concentration
range compared to 64Cu, spanning several orders of magnitude.
Remarkably high radiochemical speciﬁc activities were achieved,
particularly with 89Zr-PLA (89Zr: 154 ± 75 GBq/μmol
encapsulated drug; 38 ± 17 GBq/μmol lipid; n = 3). The
nature of the drug and the presence of a coordinating
counterion such as sodium, where relevant (PLA-Na, where
the counterion is sodium instead of ammonium, present in
PLA/PLAD/Doxil) aﬀect RLYs, further conﬁrming their
involvement. To study the eﬀect of the lipid membrane
composition in RLYs, we attempted the radiolabeling of
PROMITIL (PEGylated liposomal mitomycin C prodrug).32
This liposome does not contain encapsulated drug, and in
contrast to the other liposomes used in this study, its lipid
bilayer includes 10% of a lipophilic prodrug of mitomycin C.
Radiolabeling was compared with an identical formulation to
PROMITIL that had been loaded with ALD (PROMITIL-
ALD; 6.7 μmol/mL ALD). Interestingly, radiolabeling with
89Zr(8HQ)4 resulted in a RLY of 47.9 ± 4.1%, n = 3 for
PROMITIL and 93.5 ± 1.0%, n = 3 for PROMITIL-ALD. The
relatively high RLY of PROMITIL compared to that of
PLACEBO liposomes (48% vs <5%) is likely to be the result of
the presence of the lipophilic prodrug and retention of the
highly lipophilic 89Zr(8HQ)4 complex within the bilayer since
the labeling was not stable as conﬁrmed by complete
transchelation to serum proteins after incubation in human
serum. In contrast, radiolabeled PROMITIL-ALD showed high
in vitro serum stability (vide inf ra), further conﬁrming the
requirement of the encapsulated drug.
In Vitro Stability of Radiolabeled Liposomal Nano-
medicines in Human Serum. The stability of the radio-
metal−liposome complexes in human serum was studied over
72 h (89Zr, 52Mn) or 48 h (64Cu) by incubation at 37 °C and
analyzed using size-exclusion chromatography. Radiolabeled
liposomes were highly stable in vitro under these conditions
(Figure 1E). It should be noted that since the circulation half-
life of nanomedicines that exploit the EPR eﬀect such as stealth
liposomes (e.g., Doxil/Caelyx) in humans is in the 50−80 h
range,33 serum stabilities of ≥80% at 72 h at these conditions
are considered as excellent. Collectively, very low leakage of
radioactivity after 72 h of incubation was found for all
radiometals with liposomes containing the strongly metal-
chelating drug ALD (95.0 ± 3.7%, n = 24). The degree of
serum stability with doxorubicin showed a higher dependency
on the radiometal, with stabilities after 72 h of incubation
ranging from 79.6 ± 1.2% (n = 3, 89Zr) to 95.2 ± 2.7%, (n = 3,
52Mn). Interestingly, lower in vitro serum stabilities were
consistently observed with liposomal drug−radiometal combi-
nations that do not achieve high RLYs with micromolar
amounts of encapsulated drug (i.e., 89Zr-Doxil and 52Mn-PLA-
Na). In addition, 89Zr-PROMITIL (radiolabeled at 40% RLY)
was not stable in serum after 48 h incubation (1.0 ± 0.3%, n =
3), whereas 89Zr-PROMITIL-ALD showed excellent stability
(86.9 ± 3.2%, n = 3). The lack of serum stability for 89Zr-
PROMITIL is probably due to nonspeciﬁc weak binding of the
radiometal to the liposome due to the absence of intraliposomal
drug/chelator.
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Monitoring Liposomal Nanomedicine Distribution in
a Metastatic Mammary Carcinoma Model. The biodis-
tribution of the radiolabeled liposomes was monitored using
PET imaging with 89Zr-PLA in a metastatic mammary
carcinoma mouse model (3E.Δ.NT) established in immuno-
compromised NSG mice. This cancer model is traceable by
SPECT imaging/ﬂuorescence due to a dual-modality reporter
gene, the human sodium iodide symporter (hNIS-tagRFP), that
allows sensitive detection of viable cancer tissues (primary
tumor and metastases) using SPECT imaging with 99mTc-
pertechnetate ([99mTcO4]
−) and ﬂuorescence (GFP/RFP)
during dissection and histological studies (Figure 2 and Figure
S2).34 The imaging protocol was as follows: ﬁrst, 3E.Δ.NT/
NSG mice were injected with 89Zr-PLA (4.6 ± 0.4 MBq in 1.2
μmol phospholipid) at t = 0 followed by PET-CT imaging
(liposome biodistribution). The same mice were then injected
with [99mTcO4]
− (30 MBq) and imaged by SPECT-CT (hNIS-
positive cancer cell biodistribution, vide inf ra). This process
(apart from 89Zr-PLA injection that was only performed at t = 0
h) was repeated at t = 24 h, 72 h (n = 5), and 168 h (n = 1). In
order to conﬁrm that the presence of 99mTc was not aﬀecting
the quality of the PET study, a series of phantoms were
scanned with diﬀerent amounts of 99mTc and 99mTc/89Zr
combinations, conﬁrming that the 2 MBq of 99mTc that could
potentially be present in mice 24 h after [99mTcO4]
− injection
did not aﬀect PET image quality/quantiﬁcation. We chose 89Zr-
PLA to validate our method in vivo due to the increasing
interest in 89Zr for monitoring long-circulating biomolecules in
clinical PET studies,35 coupled with the strong metal-chelating
properties of ALD26 and its properties as an eﬃcient sensitizer
for γ−δ T-cell immunotherapy.29 SPECT-CT imaging revealed
the location of the primary tumor as well as endogenous hNIS-
expressing organs such as the thyroid, salivary glands, stomach,
and mammary glands (Figure 2D). We also found that this
tumor model develops spontaneous metastases in lymph nodes
and lungs (Figure 2B−D). CT images revealed a signiﬁcant
increase in tumor volume during the imaging study (from 0.29
± 0.09 mL at t = 1 h to 0.75 ± 0.33 mL at t = 72 h (n = 5; P =
0.017)). Accordingly, the hNIS-positive tumor volume
calculated by SPECT increased from 0.19 ± 0.08 mL at t = 1
h to 0.56 ± 0.08 mL at t = 72 h. Using these volumes, we were
able to calculate the percentage of necrotic tumor tissue over
time, by subtracting the hNIS-positive volume (SPECT) to the
total tumor volume (CT), and found no statistically signiﬁcant
changes or trends during the study with an average of 29 ± 10%
(n = 5) necrotic tissue over the 72 h study.
The PET-CT study (Figure 3A,B and Table S3) was
consistent with the stealth properties of PLA, showing mainly
blood pool uptake at t = 1 h. On the other hand, a control
experiment of free 89Zr-alendronate (89Zr-ALD) resulted in
high kidney/renal excretion and bone uptake 1 h post-
administration, as expected for a small molecule bisphospho-
nate36 and/or free 89Zr37 (vide inf ra and Figure S3). The long-
circulating nature of 89Zr-PLA is also evident from the high
signal in the heart during the study (from 31.2 ± 7.2%ID/mL
at 1 h to 8.32 ± 0.90%ID/mL at 72 h). The calculated
circulation half-life, assuming ﬁrst-order single-compartment
pharmacokinetics, is 15 h, matching that of similar mouse
studies with PEGylated liposomal bisphosphonates with
identical lipid composition38 and other PEGylated liposomes.39
The PET imaging study revealed that 89Zr-PLA accumulates
in the spleen (22.2 ± 4.0%ID/mL at 72 h), tumor (non-
necrotic, 12.0 ± 2.6%ID/mL; whole tumor, 9.2 ± 1.1%ID/mL
at 72 h), uterus (9.5 ± 0.9%ID/mL at 72 h), and bone (femur;
8.4 ± 1.8%ID/mL at 72 h) (Figure 3A,B and Table S2). We
also performed a PET-CT study using 64Cu-PLA in an ovarian
cancer model (SKOV-3/SCID-Beige) over 48 h (Figure S4 and
Table S3). This study was performed to test the versatility and
Figure 2. 3E.Δ.NT/NSG mouse model of metastatic mammary carcinoma. (A) Photographs of a representative primary tumor (T) in the
mammary gland of NSG mice under white light (left) and under excitation light showing green ﬂuorescence (center) and red ﬂuorescence
(right). (B) Lungs under white light (left) and excitation light (right), showing miliary metastatic spread. (C) Top: Metastatic lymph node
(LNmet, left axial) under white light (left) and excitation light (right) showing the presence of metastasis. Bottom: Nonmetastatic lymph node
(LN, left brachial) under white light (left) and excitation light (right) showing the absence of metastasis. (D) Maximum intensity projection
SPECT-CT image of 3E.Δ.NT/NSG mouse 1 h after injection of [99mTcO4]− (30 MBq). Uptake is observed in hNIS-expressing 3E.Δ.NT cells
in the primary tumor (T) and metastatic left axillary lymph node (LNmet) and lungs (Lumet). Endogenous hNIS-expressing organs such as
thyroid (Th), salivary glands (Sa), and stomach (St) are also visible.
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capability of our radiolabeling method to track liposomal
nanomedicines in other tumor models with diﬀerent radio-
isotopes. Results revealed a similar biodistribution proﬁle with
long circulation time and high tumor, liver, and spleen uptake
at 48 h but lacking uterus and bone uptake, which can be
explained by the diﬀerent animal model and isotope (vide
inf ra).
Increasing uptake of 89Zr-PLA in the tumor over time is
consistent with the EPR eﬀect and the long blood half-life of
these liposomes and is supported by increasing tumor-to-
muscle and tumor-to-heart/blood ratios (Figure 3D). Accu-
mulation of long-circulating liposomes in the spleen is
frequently seen with stealth liposomes and reﬂected by its
rising uptake values over time. It is important to note, however,
that the values reported for the spleen from the image-based
quantiﬁcation are an underestimate of the real uptake due to
the small size of the spleen in young NSG mice (13 ± 4 mg; n
= 9), which cannot be segmented accurately by CT due its poor
soft tissue contrast and the substantial partial volume eﬀect of
the PET signal from this organ. Hence, the volume for the
spleen used in this calculation was that of the PET signal which
results in a signiﬁcantly smaller uptake value compared to that
obtained from the ex vivo biodistribution (Table 1 and Table
S2). The uptake in liver followed a diﬀerent proﬁle to other
organs, with an increase for the ﬁrst 24 h followed by a
decrease. We found a similar liver time−activity proﬁle in the
64Cu-PLA/SKOV-3 study (Figure S4C and Table S3). This
result ﬁts well with the known role of hepatic Kupﬀer cells in
the fast uptake and subsequent metabolism of liposomal
nanomedicines, which peaks within the ﬁrst 24 h.40
Accordingly, uptake in bone increases over time as a result of
the destruction of 89Zr-PLA in the liver and/or after tissue
Figure 3. Multimodal imaging study with 89Zr-PLA in the 3E.Δ.NT/NSG mouse model of metastatic breast cancer. (A) Coronal and sagittal
SPECT-CT (top) and PET-CT (bottom) images centered at the tumors of the same animal from 1 to 72 h after injection of 89Zr-PLA (4.6
MBq in 1.2 μmol lipid). SPECT-CT images show identical biodistribution of [99mTcO4]
− over time with high uptake in endogenous hNIS-
expressing organs and hNIS-expressing tumor cells in the tumor (T) and metastatic organs (LNmet and Lumet). PET-CT images show the
increasing uptake of 89Zr over time in the primary tumor (T), spleen (Sp), liver (L), and bone (B) and decreasing uptake in blood pool/heart
(H). (B) Time−activity curves (89Zr) based on the preclinical imaging study shown in (a) (n = 5 from t = 1−72 h; n = 1 at t = 168 h). Organs
have been segregated into ascending (left) and descending uptake (right) for clarity. (C) Ex vivo biodistribution graph showing data for
selected organs at t = 72 h of 89Zr-PLA in 3E.Δ.NT/NSG mice (black bars, n = 4), 89Zr-ALD in 3E.Δ.NT/NSG mice (white bars, n = 2), and
89Zr-PLA in non-tumor-bearing NSG mice (gray bars, n = 3). **P < 0.01. Two-tailed t-test (unpaired). Full ex vivo biodistribution data at t =
72 h are available in Table 1. (D) Selected tumor to organ ratios from the 89Zr-PLA/3E.Δ.NT/NSG study (n = 4) showing an increase over
time. (E) Co-registered SPECT-PET-CT images of the primary tumor (from left to right: sagittal, coronal, transverse) showing a high degree
of colocalization and heterogeneity of the 89Zr (purple scale) and 99mTc signals (green scale) within the non-necrotic rim. (F)
Autoradiography images (left, 99mTc; right, 89Zr) of coronal slice from the same tumor as in (e) showing high degree of colocalization and
heterogeneity of both signals. (G) Fluorescence imaging of an adjacent slice of the same tumor as in (e,f) showing both areas of high
colocalization of microvasculature (CD31-positive, red) and GFP-positive (green) cancer cells (GFP, left), and low colocalization (right).
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extravasation and release of liposomal contents (free 89Zr or
89Zr-ALD) that have high aﬃnity to bone. It should be noted
that we did not observe signiﬁcant bone accumulation in the
64Cu-PLA/SKOV-3 study (Table S3), supporting the notion
that it is free/nonchelated 89Zr, and not 89Zr-ALD, that binds to
bone. However, the aﬃnity of Cu(II) toward bisphosphonates
is much lower than that of Zr(IV), and free Cu(II) would target
liver rather than bone once the 64Cu(II)-ALD complex
dissociates. We therefore cannot ﬁrmly identify the species
that are binding to bone in the 89Zr study. Similar bone uptake
values have been found with long-circulating (>24 h) 89Zr-
labeled antibodies and liposomes, suggesting that these bone-
targeting species are nonchelated 89Zr released after liposome
disassembly.19,41−43 Highly vascular organs such as the lungs
and kidneys followed the same decreasing trend in signal as the
heart/blood, as expected for long-circulating nanoparticles that
are cleared via the reticuloendothelial system (RES). One
animal from the group was further imaged at 168 h to conﬁrm
the biodistribution trend. Thus, a signiﬁcant increase of 89Zr
was observed from time point 72 to 168 h in viable tumor
tissue (from 12.0 ± 2.6 to 16.9%ID/mL) and bone (from 8.4 ±
1.8 to 13.3%ID/mL), as well as a decrease in the liver (from
18.6 ± 1.2 to 10.4%ID/mL) and heart/blood (from 8.3 ± 0.9
to 3.9%ID/mL).
Our SPECT-CT/PET-CT imaging strategy allowed us to co-
register the two modalities and study the localization of 89Zr
(PLA) and 99mTc (hNIS tumor cells) in the tumors (Figure
3E,F and Video S1). Both 89Zr and 99mTc concentrated in the
rim of the tumor with high levels of colocalization, particularly
in the basal area of the tumor in direct contact with the body of
the animal. Co-localization of 99mTc and 89Zr within the non-
necrotic rim was heterogeneous, and 89Zr (PLA) localization
did not always correspond to areas of high 99mTc uptake. We
investigated this observation further using histological studies
(vide inf ra).
Ex Vivo Tissue Distribution Analysis of Radiolabeled
Liposomal Nanomedicine. Organ biodistribution data were
obtained at the end of the imaging studies (72 h) to support
the imaging-based quantiﬁcation (n = 4) (Table 1, Figure 3C,
and Table S2). The results are in close agreement; showing
high uptake values in spleen (169 ± 49%ID/g), liver (12.1 ±
7.6%ID/g), femur (11.1 ± 3.1%ID/g), uterus (9.6 ± 6.7%ID/
g), and tumor (8.4 ± 1.6%ID/g). In addition, there was a
signiﬁcant amount of 89Zr in blood (7.8 ± 3.3%ID/g) and
other vascular organs such as the lungs (7.3 ± 2.3%ID/g).
Surprisingly, the ex vivo uptake value measured in lungs was
very similar to that from the image-based distribution (7.4 ±
0.9%ID/mL). This was unexpected since the large proportion
of air in lungs during in the in vivo study should, in principle,
result in diﬀerent %ID/g and %ID/mL values. We believe there
are three main factors that could contribute to this unexpected
result. First, metastatic lungs had a ca. 50% higher mass
compared to normal lungs. Second, there is still a signiﬁcant
amount of circulating 89Zr-PLA at this time point, which may
contribute to diﬀerent in vitro/vivo amounts present in the
lungs. Lastly, the breathing of mice under general anesthesia is
very suppressed, which may result in an overall low lung
volume measured.
Two independent ex vivo biodistribution control experiments
were performed at 72 h post-injection to validate the ﬁndings of
the tumor study with 89Zr-PLA. First, a control experiment with
89Zr-ALD in tumor-bearing mice assessed the potential
contribution of the release of intraliposomal complex/non-
chelated 89Zr in the biodistribution data of 89Zr-PLA. The
results (n = 2) showed a signiﬁcantly diﬀerent biodistribution
proﬁle, consistent with fast-clearing small bisphosphonates
and/or unchelated 89Zr, with main uptake in bone (i.e., femur)
(34.8 ± 2.8 vs 11.1 ± 3.1%ID/g; P = 0.0008) and negligible
presence in blood compared to 89Zr-PLA (0.33 ± 0.02 vs 7.8 ±
3.3%ID/g; P = 0.0396) at 72 h after injection. Tumor uptake
with 89Zr-ALD was surprisingly high (2.0 ± 0.8%ID/g), but in
agreement with recent reports in other murine tumor models
using weakly chelated 89Zr (as an oxalate complex),37 and
signiﬁcantly lower compared to the 89Zr-PLA study (8.4 ± 1.6%
ID/g; P = 0.006). We performed a second biodistribution
control study with 89Zr-PLA in non-tumor-bearing NSG mice
of the same age to investigate uterus uptake and as a control for
the presence of metastasis in the lungs. We found no signiﬁcant
diﬀerences in the %ID/g uptake values of the uterus in
comparison with data from the tumor-bearing mice (Figure 3C
and Table 1). This result conﬁrms that uterus uptake is not
related to the tumor-bearing condition. Similarly, the presence
of miliary metastases in the lungs (as detected by in vivo
SPECT/ex vivo ﬂuorescence, Figure 2B,D) had no signiﬁcant
eﬀect in the uptake of 89Zr-PLA in the lungs (7.3 ± 2.3 for
tumor mice vs 6.4 ± 0.8%ID/g for nontumor mice; P = 0.6).
The calculated uptake in metastastatic lung tissue, however, is
in the range of 9.5 ± 6.9%ID/g (n = 4) to 12.4 ± 4.8%ID/g (n
= 3, after removing one outlier), which is comparable to those
from viable primary tumor (12.0 ± 2.6%ID/mL) and metastatic
lymph nodes (16.3 ± 7.1%ID/g, vide inf ra).
Multimodal Imaging Strategy Allows Detection and
Quantiﬁcation of Liposomal Nanomedicine Uptake in
Table 1. Ex Vivo Biodistribution Data of 89Zr-Labeled PLA
or ALD
PET tracer 89Zr-ALD 89Zr-PLA 89Zr-PLA
mouse model 3E.Δ.NT/NSG 3E.Δ.NT/NSG NSG
(number of animals) (n = 2) (n = 4) (n = 3)
organ %ID/g (mean ± SD) at 72 h post-injection
kidneys 11.7 ± 8.7 3.7 ± 0.7 4.8 ± 0.6
femur 34.8 ± 2.8 11.1 ± 3.1 11.3 ± 1.1
muscle 0.4 ± 0.1 1.1 ± 0.8 0.7 ± 0.1
heart 0.52 ± 0.03 4.3 ± 1.1 3.2 ± 0.5
spleen 3.6 ± 1.2 169 ± 50 137 ± 5
blood 0.33 ± 0.02 7.8 ± 3.3 8.0 ± 1.3
liver 1.6 ± 0.3 12.1 ± 7.6 11.1 ± 0.8
intestines 0.32 ± 0.02 2.6 ± 0.5 2.4 ± 0.11
lungs 1.2 ± 0.2a 7.3 ± 2.3a 6.4 ± 0.8
lung metastasesb N/C 12.4 ± 4.8
(n = 3)c
N/A
9.5 ± 7.0 (n = 4)
stomach 0.16 ± 0.06 1.9 ± 0.8 1.0 ± 0.1
tumor (whole) 2.0 ± 0.8 8.4 ± 1.6 N/A
uterus 0.9 ± 0.8 9.6 ± 6.7 13.0 ± 2.0
metastatic lymph
nodes (LNmet)
a
6.9 ± 3.5 (n = 3) 16.3 ± 7.1
(n = 7)
N/A
normal lymph nodes
(LN)
5.6 ± 1.5 (n = 3) 3.8 ± 2.3 (n = 4) 5.0 ± 3.5
(n = 3)
aContaining metastases as assessed by hNIS-positive SPECT/
ﬂuorescence signal. bCalculated by subtracting the average mass and
%ID of nonmetastatic lungs (89Zr-PLA/NSG study) to each data from
metastatic lungs (89Zr-PLA/MTLn3E.Δ.NT/NSG study). cCalculated
by removing one outlier (1.0%ID/g) that was 8.6-fold lower than the
smallest of the rest of the data points. N/A = not applicable; N/C =
not calculated.
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Metastatic Lymph Nodes. The presence of the multimodal
reporter gene in the 3E.Δ.NT cell line allowed the detection by
SPECT and optical imaging of spontaneous metastases in the
left axillary lymph nodes (n = 4) and lungs (n = 4) (Figure
2B,C) in all the animals studied. Three more lymph nodes in
individual mice were identiﬁed as metastatic (one left brachial,
one right axillary, and one renal). The biodistribution studies
also revealed that all the hNIS-positive, and hence metastatic
lymph nodes (LNmet), had a signiﬁcant higher accumulation of
89Zr-PLA than nonmetastatic lymph nodes (LN) from the same
animals (16.3 ± 7.1 vs 3.8 ± 2.3%ID/g; P = 0.009), or LN from
tumor-free mice (16.3 ± 7.1 vs 5.0 ± 3.5%ID/g; P = 0.03)
(Figure 4A). Using this information, a closer inspection of the
PET images revealed that 89Zr was visible in the left axillary
LNmet of mice with highest uptake (Figure 4B). There was no
diﬀerence in the uptake of 89Zr-ALD in LNmet and LN (6.9 ±
3.5 vs 5.6 ± 1.5%ID/g; P = 0.6).
We studied the mechanism of 89Zr-PLA uptake in the
primary tumor and LNmet using histology (ﬂuorescence and/or
autoradiography). The autoradiographs of 99mTc distribution in
primary tumors were in accordance with the SPECT imaging
results, showing the presence of a necrotic core and a mostly
viable tumor tissue rim containing the hNIS-expressing cancer
cells (Figure 3E,F and Figure S5). The autoradiography with
89Zr was also localized to the tumor rim. Similar to what we
found in the SPECT-PET co-registration data, colocalization of
99mTc and 89Zr within the viable tumor areas was heteroge-
neous and a strong 89Zr signal did not always correspond to
areas of high 99mTc uptake. Fluorescence microscopy studies on
adjacent tumor sections using anti-CD31 antibody and the
endogenous signal from hNIS-GFP revealed a high degree of
microvascularization in the rim of the tumor and a distribution
that did not completely match that of the hNIS-positive cells
(Figure 3g). Since these liposomes accumulate in tumor tissue
via the EPR eﬀect, this result provides a potential explanation
for the diﬀerent 89Zr and 99mTc intratumoral distributions.
Similarly, we found a ca. 4-fold higher degree of micro-
vasculature density (CD31) in LNmet in comparison to that in
LN (Figure 4D, 63 ± 16 vs 16 ± 4 vessels/mm2; mean ± SEM;
P = 0.0304; t-test, one-sided, unpaired), strongly supporting
increased uptake of 89Zr-PLA by EPR eﬀect in LNmet.
DISCUSSION
Our results establish that preformed liposomal nanomedicines,
including some currently in clinical use, can be eﬃciently
labeled with PET radiometals and tracked in vivo by exploiting
the metal aﬃnity and high concentration of the encapsulated
drugs. To date, PET radiolabeling of liposomes has relied on
either the introduction of radiolabeled phospholipids or
exogenous chelators in the intraliposomal space/phospholipid
bilayer.12−23 Importantly, our technique allows radiolabeling of
preformed liposomal nanomedicines, without modiﬁcation of
their components and without aﬀecting their physicochemical
properties. In addition, it achieves high radiolabeling yields,
purities, speciﬁc activities, and in vitro/vivo stabilities that are at
least equal or signiﬁcantly improved (e.g., speciﬁc activity) to
previous PET radiolabeling methods.12−23
Our method requires the use of hydroxyquinoline
ionophores to transport the metallic radionuclides through
the lipid bilayer into the intraliposomal space, where the metal
exchanges ligand and binds to the encapsulated drug. The use
of ionophores was essential for eﬃcient radiolabeling and
attempts to label liposomes in its absence, as recently reported
for 64Cu,20 did not work in our hands for any of the radiometals
used. 8HQ, however, is extensively used in radiopharmacies for
labeling cells with γ-emitting isotopes and hence does not
Figure 4. Multimodal imaging data showing the accumulation of 89Zr-PLA in metastatic lymph nodes (LNmet). (A) Ex vivo biodistribution data
at t = 72 h showing the uptake of 89Zr-PLA in LNmet (red circles, 3E.Δ.NT/NSG mice, n = 7), nonmetastatic lymph nodes (LN) (blue circles,
3E.Δ.NT/NSG mice, n = 4), LN (blue triangles, non-tumor-bearing NSG mice, n = 3); or 89Zr-ALD in LNmet (red squares, 3E.Δ.NT/NSG
mice, n = 3), LN (blue squares, 3E.Δ.NT/NSG mice, n = 3); **P < 0.01, *P < 0.05, two-tailed t-test (unpaired). (B) Coronal and sagittal
SPECT-CT (top) and PET-CT (bottom) images centered at the LNmet of same animal from at 72 h after injection of
89Zr-PLA. (C)
Fluorescence microscopy images of sections of LNmet (top) and LN (left brachial, bottom). A high degree of metastasis (green) and
microvasculature density (red) is observed in LNmet but not in LN. Scale bar is 250 μm. (D) Quantiﬁcation of microvasculature density in
LNmet (black bar) and LN (gray bar) from ﬂuorescence imaging, *P < 0.05; t-test, one-sided, unpaired, mean ± SEM; n = 2).
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represent a signiﬁcant barrier for clinical translation30 and has
been recently been used for labeling cells with 89Zr.31 2HQ has
been previously used to radiolabel with 64Cu liposomes loaded
with the chelator DOTA,14 while here we report the use of
8HQ with the PET tracers 89Zr and 52Mn.
We tested the radiolabeling method with three diﬀerent PET
radiometals of suﬃcient radioactive half-life to track long-
circulating nanomedicines and four PEGylated liposomes of
known/promising preclinical and clinical eﬃcacy.29,33 These
liposomes contained diﬀerent combinations of drugs but have
identical phospholipid chemical composition and physicochem-
ical properties. The presence of a water-phase encapsulated
drug with metal-chelating properties is a requirement for
eﬀective labeling, as proven by the lack of eﬃcient and stable
radiolabeling in its absence, even when the lipid bilayer contains
highly lipophilic components such as the mitomycin C prodrug.
The high intraliposomal concentration of alendronate or
doxorubicin allows for very eﬃcient RLYs over a remarkably
wide range of submicromolar drug concentrations (i.e., as much
as 5 orders of magnitude with 89Zr) and consequently
remarkably high speciﬁc activities in the range of GBq/μmol.
This property is key for facilitating clinical translation since it
avoids puriﬁcation steps and would allow the injection of
submicromolar concentrations of the therapeutic liposomal
nanomedicine (microdosing), hence minimizing any potentially
undesirable chemotherapeutic toxicity eﬀects to patients from
the imaging study. For example, the typical therapeutic dose of
Doxil/Caelyx for a 70 kg individual contains approximately 546
μmol of phospholipid, and a typical imaging dose for PET
imaging a long-circulating tracer such as an antibody labeled
with 89Zr is 75 MBq.44 According to our experiments, such an
amount of 89Zr radioactivity, suﬃcient for human PET studies,
could be loaded into a Doxil/Caelyx dose of just 0.034 μmol of
phospholipid, which is 6 × 10−3% of the therapeutic dose and
far below the accepted maximum value for microdosing (i.e., 1%
of the therapeutic dose). According to our results, other
combinations that would allow microdose PET clinical imaging
under these conditions (i.e., those that achieve speciﬁc activities
≥14 MBq/μmol phospholipid) would be 89Zr/52Mn/64Cu-
PLA, 89Zr-PLA-Na, 89Zr/52Mn-PLAD, 89Zr-Doxil, and possibly
52Mn-Doxil.
The radiolabeling yields follow basic metal coordination
chemistry principles as expected for the formation of the PET
radiometal−drug complexes. Thus, RLYs were consistent with
Pearson’s hard and soft acid−base theory. Hence, the
bisphosphonatea highly anionic and oxygen-rich drug
showed high aﬃnity for the two hard Lewis acids, Zr(IV) and
Mn(II). On the other hand, Cu(II), a borderline Lewis acid,
shows lower aﬃnity for oxygen-based ligands. Doxorubicin, a
nonanionic metal chelator, consequently showed lower RLYs
(89Zr, 52Mn) or no radiolabeling (64Cu) at the concentration
ranges tested. The presence of Na+ as intraliposomal
counterion for alendronate in PLA-Na blocks radiolabeling
with 64Cu, compared to the same formulation with NH4
+ as
counterion (PLA) (Figure 1D). This result could be explained
by the chemical nature of Na+, a coordinating metal ion and
hard Lewis acid with strong aﬃnity for oxygen donors. On the
other hand, NH4
+, a nonmetallic cation unable to form
coordination bonds with bisphosphonates, is not able to
compete with the radiometal. We did not observe this eﬀect
with 89Zr or 52Mn, most likely due to their higher oxophilicity
and charge (+4 and +2 vs +1), which successfully compete with
the Na+ ion.
Collectively, liposomes radiolabeled using this method
showed excellent stability in human serum at 37 °C over 48
h (93.8 ± 4.6%; n = 10; 89Zr, 52Mn, and 64Cu) and 72 h (92.8
± 6.4%; n = 8; 89Zr and 52Mn). These compare favorably to
other reported radiolabeled liposomes and, importantly, match
the circulation half-lives of current long-circulating liposomal
nanomedicines in the clinic (i.e., 15−30 h in rodent; 50−80 h in
humans). The human serum stability results showed metal and
drug dependency, supporting our hypothesis and providing
“perfect matched pairs” to maximize stability (e.g., 89Zr/52Mn
and ammonium alendronate; 89Zr and sodium alendronate;
52Mn and doxorubicin). Our studies also suggest that a
requirement to achieve high in vitro serum stabilities with a
given PET radiometal using our method is to achieve
radiolabeling yields of >60% in the presence of ca. 1 μmol
encapsulated liposomal drug.
The in vivo studies with 89Zr-PLA and 64Cu-PLA in the
3E.Δ.NT mammary carcinoma and SKOV-3 ovarian cancer
models, respectively, showed the expected pharmacokinetics
and biodistribution of stealth liposomes (i.e., long circulation
time, high tumor uptake, and metabolism via the RES),
conﬁrming the utility of this radiolabeling technique to track
liposomal nanomedicines in vivo with diﬀerent PET isotopes
over a long period of time. The high uptake values in both
tumors (6.7 ± 3.2%ID/tumor at 72 h p.i. in 3E.Δ.NT model
and 7.4 ± 0.8%ID/tumor at 48 h p.i. in SKOV-3 model)
compare favorably to the recent median value of 0.7%ID/tumor
from a multivariate analysis on the compiled data on this ﬁeld
reported recently by Wilhelm et al.45 An unexpected ﬁnding
during the 89Zr-PLA studies was a high uptake in the uterus of
NSG mice. The fact that we did not detect such uptake in the
64Cu-PLA study in female SCID-Beige mice leads us to
hypothesize that this result is speciﬁc to NSG mice and could
be due high levels of vascularization, blood ﬂow, and
permeability in this strain, and further experiments would be
required to conﬁrm this hypothesis. Nonetheless, it is only by
labeling and imaging nanomedicines at the whole body level
that we can identify unexpected areas of uptake such as this.
The multimodal (PET/SPECT/ﬂuorescence) reporter-gene
strategy used allowed us to sequentially image the same animals
both in PET (89Zr-PLA) and in SPECT (99mTc-hNIS reporter
gene) at diﬀerent time points and hence identify the location of
viable cancer cellsincluding spontaneous metastasesand
89Zr-PLA in tissues. We found consistent colocalization in the
viable tissue areas of primary tumors but also a high degree of
heterogeneity within these areas. Fluorescence histological
studies strongly suggest that this result is related to diﬀerent
levels of vascularization within the tumor (which do not always
colocalize with areas of high density of viable hNIS-expressing
cancer cells) and to the well-known EPR mechanism of tumor
uptake of stealth nanoparticles.
In addition, metastastic tissues (lymph nodes and lung
metastases) also showed a signiﬁcant high uptake of 89Zr-PLA
compared to controls, possibly driven by a higher level of
microvascularization and EPR eﬀect. To the best of our
knowledge, EPR-driven uptake of liposomal nanomedicines in
metastatic lymph nodes has not been observed before in small
animal studies using nuclear imaging. There is, however,
precedent from clinical studies. Thus, using a DTPA-loaded
stealth liposome labeled with the SPECT isotope 111In,
Harrington et al. detected metastatic lymph nodes in breast
cancer and head and neck patients.7 By using PET-labeled
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nanomedicines and technology, such as the one reported here,
these and smaller metastatic lesions in lymph nodes and other
organs will be detected with better sensitivity and spatial
resolution.
Our strategy has potential limitations for clinical translation.
The ﬁrst one, which applies to all radioactivity-based imaging
agents with long circulation times and isotopes with long
radiation half-lives, is patient radiation dose. Based on our
animal imaging study with 89Zr-PLA, we have estimated a
human mean radiation dose of 0.9 ± 0.2 mSv/MBq. This is a
high radiation dose and would limit the number of times a
patient may undergo such an imaging study, but it is worth
mentioning that there may be a signiﬁcant error associated with
this estimation as a result of scaling the data from mouse to
man, and recent reports from clinical immuno-PET studies with
89Zr-labeled antibodies have calculated radiation doses close to
this value (e.g., up to 0.7 mSv/MBq).44 In addition, it is
expected that future improvements in clinical PET technology
may allow the detection of lower amounts of radioactivity, by as
much as 40-fold, and hence 1/40th the radiation dose to
patients.44,46 Another limitation of our method is the
requirement of a drug with chelating properties. However,
since many drugs contain well-established metal chelator motifs
and intraliposomal drug concentrations are very high (10−1 M
range), we believe that a great number of current and future
liposomal drugs (Figure 1A and Figure S1), such as those
studied here, will be amenable for eﬃcient radiolabeling
without modiﬁcation, thus enabling the development of a
powerful theranostic tool.
CONCLUSIONS
In summary, we have developed a simple and eﬃcient method
for radiolabeling preformed liposomal nanomedicines that
contain a metal-chelating drug such as an aminobisphosphonate
with metallic PET isotopes. As expected from the proposed
radiometal−drug interaction, the drugs tested (alendronate and
doxorubicin) have diﬀerent aﬃnities to the metals explored in
this study (89Zr, 52Mn, and 64Cu), and the labeling yields and in
vitro stabilities obtained are in accordance with the expected
metal−ligand aﬃnities from basic coordination chemistry
principles. Radiolabeled liposomes containing a bisphosphonate
showed excellent human serum stabilities (≥95%) with all
radiometals tested, which is consistent with the strong chelating
properties of these molecules. Liposomes that contain a weaker
chelator such as doxorubicin showed a higher aﬃnity and
stability with 52Mn. To demonstrate the feasibility of this
method in vivo, we used preclinical PET-CT to study the
biodistribution and pharmacokinetics of a bisphosphonate-
loaded PEGylated liposome (PLA) radiolabeled with 89Zr and
64Cu in two diﬀerent tumor models (breast and ovarian
cancer), showing the expected biodistribution of stealth
liposomes and a high uptake in primary tumors (both models)
and lymph node/lung metastases (breast cancer model only).
Recent work by Peŕez-Medina et al. have used a PET
nanoreporter technology to demonstrate that PET-radiolabeled
nanoparticles can predict the eﬃcacy of nanomedicinal
therapies in animal models.22 Hence, we foresee that the
method described here may provide a powerful developmental
theranostic tool for many current and future liposomal drugs
and will allow the study of their biodistribution prior to
treatment for patient selection. We expect this work may
facilitate the inclusion of a pretreatment (and possibly on-
treatment) imaging stage for the improvement of the clinical
value of liposomal drugs that encapsulate metal-chelating drugs.
METHODS
Materials and Instrumentation. Reagents and materials were
obtained from commercial sources and used as received unless
otherwise noted. All tools for molecular biology were from NEB
(Hitchin, UK). Mowiol was from ICN (Costa Mesa, CA, US). 64Ni
(99.6% isotopically enriched) was purchased from CK GAS Products
Ltd. (Hampshire, UK). Organic solvents were of HPLC grade. Water
(Type I, 18.2 MΩ·cm) was obtained from an ELGA Purelab Option-Q
system. For TLC studies, ITLC-SG strips (Agilent, UK) or 0.5 × 10
cm silica gel 60 F-254 aluminum-backed plates (Merck KGaA,
Germany) were used. TLC/ITLC plates were scanned with a Mini-
Scan TLC scanner equipped with a FC3600 detector optimized for the
detection of β+ particles (Lablogic, UK). Radioactivity in samples was
measured with a CRC-25R dose calibrator (Capintec, USA) or a 1282
CompuGamma γ counter (LKB Wallac, Finland). Millex IC 0.22 μm
(13 mm) hydrophilic PTFE ﬁlters (Millipore, USA) were used
throughout this study. Size-exclusion chromatography was performed
with a GE ÄKTA Explorer system using PBS as eluent. Dynamic light
scattering and ζ-potential measurements were performed with a
Zetasizer Nano ZS instrument (Malvern Instruments, UK) at 25 °C.
Human serum was obtained from a healthy volunteer and ﬁltered
through a 0.2 μm ﬁlter before use.
Liposome Components and Sources. The following components
were used: hydrogenated soybean phosphatidylcholine (HSPC)
(Lipoid, Germany), methoxypolyethylene glycol distearoyl
phosphatidylethanolamine (mPEG2000-DSPE) (Biolab, Jerusalem,
Israel), cholesterol (Chol) (Sigma, St. Louis, MO), alendronic acid
(Teva, Israel, and Tokyo Chemical Industry Co Ltd., Japan),
doxorubicin (Teva, Israel), PEGylated liposomal doxorubicin (Janssen
Pharmaceuticals, NJ, USA, commercial name Doxil or Caelyx),
mitomycin C prodrug (MLP) conjugate: 2,3-(distearoyloxy)propane-
1-dithio-4′-benzyloxycarbonyl-MMC (Aptuit-Laurus, Hyderabad,
India).
Antibodies. Mouse monoclonal anti-CD31 and anti-GAPDH
antibodies were purchased from Abcam (Cambridge, UK) and
GeneTex (Hsinchu City, Taiwan R.O.C.), respectively. The rabbit
polyclonal anti-NIS antibody SJ1 was from Imanis Life Sciences
(Rochester, MN, US). All ﬂuorescent secondary antibodies conjugated
to either Cy3 or Cy5 were from Jackson Immunoresearch (West
Grove, PA, US). Secondary anti-rabbit and anti-mouse antibodies
conjugated to horseradish peroxidase (HRP) for immunoblotting were
purchased from Dako (Thetford, UK).
Radionuclides. 89Zr. No-carrier-added zirconium-89 (radionuclidic
purity >99.9%) was purchased from PerkinElmer and produced at the
BV Cyclotron, Amsterdam. Solutions were received and stored as
H4[
89Zr(oxalate)4] in aqueous oxalic acid (1 M) and were titrated with
0.5 M ammonium acetate until pH 6−7 (measured using pH strips),
just before use. Speciﬁc activity: ≥150 GBq/μmol versus DFO
titration.
52Mn. 52Mn was produced at The Hevesy Laboratory at the
Technical University of Denmark based upon modiﬁcations to the
methods presented by Graves et al.47 Brieﬂy, natural chromium
powder (100−325 mesh 99.99%, Alfa Aesar) was pressed into a silver
backing and bombarded with 90° incident protons at 16 MeV and 20
μA for 3 h on a GE PETtrace cyclotron. Following irradiation, the
irradiated chromium target was dissolved in concentrated hydrochloric
acid and diluted into ethanol. 52Mn was concentrated and puriﬁed
from the bulk chromium by three sequential column extractions and
elutions from AG1x8 (Biorad) strong anion exchange resin, ultimately
providing 52MnCl2 in 2 mL of 0.1 M HCl. This solution was carefully
titrated before use with a 0.5 M ammonium acetate solution until the
pH was 7. Speciﬁc activity: 2.6 GBq/μmol versus DOTA titration, cold
trace metals present (ng/MBq of 52Mn): Cr = 60, Cu = 9, Co = 4, Fe
= 43, Mn = 2.4.
64Cu. 64Cu was produced at the PET Imaging Centre, St. Thomas’
Hospital, London, UK, by proton bombardment of 10−15 mg of 64Ni
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(99.6% isotopically enriched, CK GAS products Ltd., Hampshire,
UK), electroplated onto a gold disc at 25 μA for 4−6 h in a CTI RDS
112 11 MeV cyclotron using purpose-built targetry. Puriﬁcation of
64Cu was undertaken using established procedures.48 Radionuclidic
purity was conﬁrmed by γ-ray spectroscopy (Ortec DSPEC Plus
HPGe γ-ray spectrometer) to be >99%. 64CuCl2 was obtained in HCl
solution and transformed into 64Cu(OAc)2 by evaporation of the
solution to a small volume and addition of small volumes of 0.5 M
ammonium acetate buﬀer (pH 5.5), until the pH reached that of the
buﬀer. Purity was conﬁrmed by TLC (Rf = 0.66) with silica gel plates
using 15 mM EDTA in 10% ammonium acetate/MeOH (50/50) as
the mobile phase. Speciﬁc activity: ca. 11 GBq/μmol versus TETA
titration.48
99mTcO4
−. 99mTc-pertechnetate in saline was eluted from a Drytec
generator (GE Healthcare, Amersham, UK) from the Radiopharmacy
at Guy’s and St. Thomas’ Hospital Nuclear Medicine Department at
King’s College London, UK.
Synthesis of PEGylated Liposomal Alendronate (PLA).
Liposomes were prepared by the standard method of ethanol injection
into an aqueous buﬀer, followed by extrusion through polycarbonate
membrane ﬁlters down to 0.05 μm pore size. The lipid components,
HSPC, mPEG-DSPE, and Chol at mol ratios of 55, 40, and 5%,
respectively, were weighed and dissolved in ethanol. The buﬀer was a
solution of 250 mM alendronic acid (ALD) dissolved in H2O and
adjusted to pH 6.0 with 25% ammonium hydroxide at 60 °C to form a
salt of ALD(NH4)2. The resulting liposomes were then processed by
serial size extrusion in a high-pressure extruder device (Lipex
Biomembranes, Vancouver, BC) with temperature control at 60 °C
through ﬁlters with pore sizes from 1 to 0.05 μm. Non-encapsulated
ALD was removed by dialysis against a buﬀer of 5% dextrose with 15
mM histidine, pH 7.0, followed by passage over a Dowex anion
exchange resin. The liposomes were sterilized by ﬁltration through
0.22 μM ﬁlters and stored in Vacutainer tubes at 4 °C. Phospholipid
(PL) and ALD content were determined after Folch extraction (8:4:3
CHCl3/MeOH/H2O or sample) where the lower lipophilic phase
contains the organic phosphate (PL) and the upper phase contains the
inorganic phosphate (ALD). Samples of each phase were assayed by
the Bartlett method to determine phosphorus. ALD quantiﬁcation
based on phosphorus content was conﬁrmed at the Nanotechnology
Characterization Laboratory (NCL, Frederick, MD, USA).
Synthesis of PEGylated Liposomal Alendronate−Doxorubi-
cin (PLAD). PLAD was synthesized using a gradient-induced loading
of doxorubicin (Dox): PLA, prepared as described above, was
incubated with a solution of 10 mg/mL of Dox in 5% dextrose at
ALD-Dox molar ratios ranging between 2 and 0.5. The incubation was
with gentle shaking for 60 min at a temperature of 60 °C, followed by
ice−water cooling immediately upon end of incubation. The resulting
liposome suspension was passed through a Dowex cation exchange
resin to remove any non-encapsulated Dox and was sterilized using
0.22 μm ﬁlters. Dox concentration was measured spectrophotometri-
cally by absorbance at 480 nm after dilution and disruption of the
liposomes in acidiﬁed (0.075 N HCl) 10:90 H2O/t-BuOH solution.
The ﬁnal concentration of Dox in the formulation was adjusted to 2.0
mg/mL by further dilution with the dialysis buﬀer (5% dextrose/15
mM histidine). Dox quantiﬁcation was conﬁrmed at the Nano-
technology Characterization Laboratory (NCL, Frederick, MD, USA).
Synthesis of PROMITIL. PEGylated liposomal mitomycin C lipid-
based prodrug (PROMITIL) was prepared and characterized as
previously reported49 and provided by Lipomedix Pharmaceuticals
Ltd.
Synthesis of PROMITIL-ALD. PEGylated liposomal mitomycin C
lipid-based prodrug containing encapsulated ALD (PROMITIL-ALD)
was prepared as PROMITIL49 with the same lipids but using a HSPC/
Chol/PEG-DSPE/MLP 55/30/5/10 molar ratio and using a 155 mM
ALD(NH4)2 buﬀer solution (pH 6.5) during liposome formation. The
resulting liposomes were then processed by serial size extrusion in a
high-pressure extruder device (Lipex Biomembranes, Vancouver, BC)
with temperature control at 60 °C through ﬁlters with pore sizes from
1 to 0.05 μm. Non-encapsulated ALD was removed by dialysis against
a buﬀer of 5% dextrose in 15 mM HEPES, pH 7.0. The liposomes
were sterilized by ﬁltration through 0.22 μM ﬁlters and stored in
Vacutainer tubes at 4 °C. Phospholipid and ALD content were
determined after Folch extraction (8:4:3 CHCl3/MeOH/H2O or
sample) where the lower lipophilic phase contains the organic
phosphate (PL) and the upper phase contains the inorganic phosphate
(ALD). Samples of each phase were assayed by the Bartlett method to
determine phosphorus. The batch used for these studies contained
30.2 μmol/mL PL, 2.2 mg/mL ALD, and 6.7 mg/mL MLP and
showed a mean hydrodynamic size of 111 nm (PDI = 0.088) by DLS.
Synthesis of 89Zr-ALD. H4[
89Zr(oxalate)4] in aqueous 1 M oxalic
acid (10 μL, 14 MBq) was mixed with 360 μg of ALD in 300 μL of
PBS. The pH of the solution was increased to 7 by addition of 10 μL
of a 1 M Na2CO3 solution and the mixture heated at 50 °C for 5 min.
The formation of the complex was conﬁrmed by ITLC-SG strips with
a 20 mM sodium citrate mobile phase. Using this system, 89Zr-ALD
has a Rf = 0, whereas H4[
89Zr(oxalate)4] has a Rf = 0.9.
Radiolabeling of Liposomes. To radiolabel the liposomes
(PLACEBO, PLA, PLA-Na, PLAD, Doxil, PROMITIL, PROMITIL-
ALD), an aliquot of the radiometal−ionophore solution (vide inf ra)
was mixed with a double volume of the liposomes at the desired
concentration in PBS or saline (chelexed) and incubated at 50 °C for
30 min with constant shaking. Speciﬁc details including concentrations
of liposomes and radiometal−ionophore complexes, as well as
radiolabeling yields and maximum speciﬁc activities, are shown in
Table S4. To calculate the radiolabeling yield and/or purify the
radiolabeled liposomes, the mixture (or an aliquot) was loaded into a
Sephadex-G25 minitrap column (GE Healthcare Life Sciences, UK)
using the manufacturer’s protocol and eluted using PBS in 250 μL
fractions. Fractions containing the liposomes (ﬁrst 750 μL) and
column were measured for radioactivity to provide the radiolabeling
yield. If required, radiolabeled liposomes can be concentrated using
Vivaspin 500 30K MWCO spin ﬁlters (GE Healthcare, UK).
Synthesis of Ionophore−Radiometal Complexes. 64Cu(2HQ)2.
This complex has been reported previously14 but was synthesized by a
diﬀerent route. To make the stock solution of the ionophore (2HQ), 3
mg was dissolved in 300 μL of absolute EtOH (assisted by mild
heating), and this solution was subsequently mixed with 300 μL of a
0.5 M ammonium acetate buﬀer pH 5.5. To form the 64Cu-ionophore
complex, 60 μL of the 2HQ stock solution (300 μg of ionophore) was
mixed with 200 μL of the buﬀered 64Cu(OAc)2 solution, and this
mixture was incubated at room temperature for 15 min. Quality
control was performed using a 1-octanol/H2O solvent extraction
method and calculating its partition coeﬃcient. The same measure-
ment was carried out with unchelated 64Cu as a control. 64Cu(2HQ)2
has a logPoctanol/water = 0.91 ± 0.07 (n = 3), whereas for unchelated
buﬀered 64Cu, this value is logPoctanol/water = −0.11 ± 0.12 (n = 3).
89Zr(8HQ)4.
89Zr(8HQ)4 was synthesized and characterized
following a previously published protocol.31
52Mn(8HQ)2. To make the stock solution of the ionophore, 3 mg
was dissolved in 300 μL of absolute EtOH (assisted by mild heating)
and subsequently mixed with 300 μL of a 0.5 M ammonium acetate
solution pH 7. Thirty microliters of this solution (150 μg of
ionophore) was mixed with 200 μL of the buﬀered 52Mn solution, and
this mixture was incubated at room temperature for 15 min. The pH of
the reaction solution was tested to conﬁrm it was 7. Quality control
was performed using a 1-octanol/H2O solvent extraction method and
comparing with unchelated buﬀered 52Mn as a control. 52Mn(8HQ)2
has a logPoctanol/water = 0.69 ± 0.25 (n = 3) compared to that of
unchelated 52Mn (logPoctanol/water = 0.07 ± 0.04; n = 3).
In Vitro Stability Studies in Human Serum. Radiolabeled
liposomes were mixed with human serum (10% v/v) and incubated at
37 °C with gentle shaking for 48 h (64Cu) or 72 h (89Zr, 52Mn). The
stability was tested by injecting 0.5 mL of this mixture into a size-
exclusion chromatography column Superose 6 10/300 GL column
(GE Healthcare, UK) at a ﬂow rate of 0.5 mL PBS buﬀer/min. Using
this system, liposomes elute as a single peak between fractions 8 and
11 mL, and serum proteins elute as two main peaks between 15 and 25
mL. Small molecules elute at fractions between 25 and 40 mL. All
fractions were γ-counted, and the column was monitored to conﬁrm
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the absence of remaining activity. To measure the percentage of
radiolabeled liposomes, the following formula was used:
= ×
+
+
−
−
−
% stable liposomes (counts min (liposome fractions) 100)
/(counts min (liposome fractions)
counts min (protein
small molecule fractions))
1
1
1
Cell Line Generation and Culture. MTLn3E mammary
adenocarcinoma cells50,51 (a kind gift of Dr. E. Sahai, CRUK London
Research Institute) were rendered more metastatic by overexpression
of a desensitization-defective chemokine receptor CXCR4 mutant
(truncation by the last 34 amino acids of its C-terminus).52,53 This
highly metastatic cell line spontaneously spreads from orthotopically
grown (mammary fat pad) primary tumors as recently demonstrated
by whole-body in vivo cancer cell tracking.34 The cells were modiﬁed
to stably express the human sodium iodide symporter (hNIS) fused to
the ﬂuorescent reporter TagRFP to enable multiscale multimodal in
vivo cell tracking and ex vivo confocal ﬂuorescence microscopy-based
conﬁrmation of the presence in harvested tissues. Brieﬂy, the DNA of
human NIS was ampliﬁed from cDNA by PCR and subcloned between
the XhoI and EcoRI sites of pTagRFP-N1 (Evrogen, Moscow, Russia),
yielding NIS C-terminally fused to TagRFP (NT). Primer sequences
used for cloning of NIS-TagRFP were 5′-TTTCTCGAGGCCAC-
CATGGAGGCCGTGGAGACCGGGGAACGG-3′ (forward) and 5′-
CCGGAATTCCGAGGTTTGTCTCCTGCTGGTCTCG-3′ (re-
verse). This construct was then subcloned into the retroviral
expression vector pLPCX (Clontech, Saint-Germain-en-Laye, France)
and conﬁrmed by sequence analysis. Subsequently, retroviruses were
produced by standard techniques in 293T cells. Retroviruses were then
used to infect MTLn3E.Δ34-CXCR4 (3E.Δ) cells. Stably NT-
expressing cells lines were obtained post-infection by selection with
puromycin (2 μg/mL) and subsequent FACS sorting (3E.Δ.NT).
MTLn3E cells and all derived cell lines were maintained in an
atmosphere of 5% CO2/95% air in αMEM medium (Sigma,
Gillingham, UK) supplemented with 5% FBS (BioSera, Uckﬁeld
East, UK), with admixtures of selection antibiotics (puromycin and/or
hygromycin) when necessary. 293T cells (ATCC) were grown in
Dulbecco’s modiﬁed MEM (Sigma) supplemented with 10% FBS in
an atmosphere of 5% CO2/95% air. In addition, all growth media
contained 10 mg/mL L-glutamate, 100 U/mL penicillin, and 0.1 mg/
mL streptomycin. All cell lines were regularly (≤3 month intervals)
tested for mycoplasma (LookOut mycoplasma PCR detection kit,
Sigma) and found to be negative throughout the study.
Flow Cytometry. For ﬂow cytometric analysis, cells were
harvested by short trypsinization, washed in PBS, and resuspended
in PBS containing 2% (w/v) bovine serum albumin (BSA) and 0.1%
(w/v) ethylenediaminetetraacetic acid (EDTA). Cells were analyzed
on a FACSCalibur ﬂow cytometer (BD Bioscience) using the FL-1
(for GFP ﬂuorescence) and FL-3 (for TagRFP ﬂuorescence) channels.
Immunoblot Analysis. Brieﬂy, cells were lysed in 1.5-fold sample
buﬀer (1.5× LDS; 92.5 mM Tris/HCl pH 8.5, 0.75% (w/w) lithium
dodecylsulfate, 3.75% (w/w) glycerol, 0.5 mM EDTA, 0.2 mM sodium
vanadate, 10 nM calyculin A, 50 mM sodium ﬂuoride, 1040 μM
AEBSF, 800 nM aprotinin, 40 μM bestain, 14 μM E64 protease
inhibitor, 20 μM leupeptin, 15 μM pepstatin A), and the protein
concentrations of the resulting lysates were determined using the BCA
protein assay kit (Thermo Fisher, Waltham, MA, US). Equal amounts
of protein were supplemented with 100 mM DTT and 0.06 mM Serva
Blue G250 (Serva, Heidelberg, Germany), boiled, and subjected to
electrophoresis using SDS-PAGE before being transferred to PVDF
Immobilon membranes (EMD Millipore, Watford, UK). Membranes
were blocked with 4% (w/w) BSA in TBS-T for 30 min, followed by
incubation with the indicated primary antibody overnight at 4 °C,
washed four times with TBS-T, and incubated with the appropriate
HRP-conjugated secondary antibody for 60 min at room temperature.
The signal was detected with the ECL kit (Thermo Fisher, Waltham,
MA, US) following the manufacturer’s instructions.
Fluorescence Microscopy of Cells. Cells were grown on acid-
treated glass coverslips to the desired cell densities and then ﬁxed in
4% (w/v) paraformaldehyde (PFA) for 15 min. Subsequently, they
were permeabilized with 0.25% (v/v) Triton X-100, blocked with 1%
(w/v) BSA, stained for nuclei using Hoechst 33342 (Merck,
Darmstadt, Germany), and mounted in Mowiol containing 2.5%
(w/v) Dabco as an antifade. Samples were imaged using a Nikon
Eclipse Ti wide-ﬁeld ﬂuorescence microscope equipped with a Plan
Apochromat 20×/0.5 NA air objective (Nikon, Tokyo, Japan).
In Vitro Radiotracer Uptake in NIS-Expressing Cells. On the
day before the experiment, 5 × 105 cells per well were seeded in a 24-
well plate. Cells were washed with HBSS (containing Ca2+ and Mg2+),
and 500 μL of HBSS was added to each well. If blocking of NIS
function was desired, 10 μL of a 500 μM NaClO4 solution was added
for 20 min. Subsequently, 0.1 MBq of 99mTcO4
− was added to each
well and incubated for a further 30 min. Supernatant of each well was
removed, wells were washed three times with 1 mL of ice-cold HBSS,
and then 500 μL of 1 M NaOH was added to lyse the cells. The
supernatant and washings of each well were pooled. Thirty microliters
of each pooled supernatant/washings and cell lysate was measured
with a γ counter. The total activity in each pooled supernatant and cell
lysate was calculated as follows:
=
×
+
−
−
−
% activity per well (counts min (cell lysate OR supernatant)
100)/(counts min (cell lysate)
counts min (supernatant))
1
1
1
Animal Experiments. All animal experiments were approved by
the UK Home Oﬃce and an ethical review panel, and all requirements
dictated by UK legislation and the above committees were met. All
immunocompromised mice were housed within ﬁlter-top cages in
Scantainer units in approved facilities and given food and water ad
libitum. All mice were anesthesized with isoﬂurane (3% Vet Tech
Solutions Ltd.) before injection of radiotracers.
3E.Δ.NT/NSG Tumor Model. Young adult (5−6 weeks old) female
NOD scid gamma mice (NSG; genotype: NOD.Cg-Prkdcscid Il2rgtm1Wjl/
SzJ (005557)) were obtained from Charles River (UK) and housed for
2 days before tumor initiation. 3E.Δ.NT cells were trypsinized, washed
with prewarmed HBSS (without Ca2+ and Mg2+), resuspended,
counted, and aliquots of 5 × 105 cells in 50 μL of HBSS were injected
s/c into the left mammary fat pad between nipples four and ﬁve. Once
palpable, tumor volumes were measured with calipers using the
following formula: V = π/6lwd, where l is length, w is width, and d is
depth. Imaging studies started 21 days after tumor inoculation.
SKOV-3/SCID-Beige Tumor Model. Young adult (5−6 weeks old)
female SCID-Beige mice were obtained from Charles River (UK) and
housed for 2 days before tumor initiation. SKOV3-ﬀLuc cells (Caliper)
were trypsinized, washed with PBS (without Ca2+ and Mg2+),
resuspended, counted, and aliquots of 2 × 106 cells in 50 μL of PBS
were injected s/c into the left ﬂank. Once palpable, tumor volumes
were measured with calipers using the following formula: V = π/6lwd,
where l is length, w is width, and d is depth. Imaging studies started 72
days after tumor inoculation.
In Vivo Imaging and Analysis of Organ Distribution. PET/
SPECT Multimodal Study with 3E.Δ.NT/NSG Model. Mice were
anesthetized with isoﬂuorane (1.5−2%) during all imaging sessions.
89Zr-PLA (4.6 ± 0.4 MBq in 1.2 μmol phospholipid; co-injected with
empty liposomes to achieve a total injected lipid dose of 4 μmol, 160
μL) or 89Zr-ALD (4.4 MBq, 100 μL) was injected i.v. at t = 0 h, and
imaging was performed after 10 min ﬁrst by PET/CT (imaging of
radiolabeled liposomal drugs), followed by injection of 100 μL of a
99mTcO4
− solution (30 MBq) in saline (at t = 1 h) and SPECT/CT
imaging (imaging of tumor and metastases). PET/CT imaging was
performed for 45 min on a nanoScan in vivo PET/CT preclinical
imager (Mediso Medical Imaging Systems, Budapest, Hungary).
SPECT/CT imaging was performed after 30 min after i.v. injection
of 99mTcO4
− using a NanoSPECT/CT Silver Upgrade (Mediso,
Hungary) for 30 min with 1 mm collimators. PET-CT and SPECT-CT
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were repeated in the same sequence at t = 24, 72 (n = 5), and 168 h (n
= 1) for 89Zr-PLA or t = 24, 72 h (n = 2) for 89Zr-ALD.
PET-CT Study with SKOV-3/SCID-Beige Model. Mice were
anesthetized with isoﬂuorane (1.5−2%) during all imaging sessions.
64Cu-PLA (14.2 MBq in 1.2 μmol phospholipid; co-injected with
empty liposomes to achieve a total injected lipid dose of 4 μmol, 160
μL) was injected i.v. at t = 0 h, and imaging was performed after 10
min by PET/CT (imaging of radiolabeled liposomal drugs) for 45 min
on a nanoScan in vivo preclinical imager (Mediso, Hungary). PET-CT
was repeated at t = 24, 48 h (n = 3).
All PET/SPECT/CT data sets were reconstructed using a Monte
Carlo based full 3D iterative algorithm (Tera-Tomo, Mediso Medical
Imaging Systems, Budapest, Hungary). Decay correction to time of
injection was applied. CT images were obtained with 55 kVp tube
voltage, 1200 ms exposure time in 360 projections. All the images were
analyzed using VivoQuant software (inviCRO, USA), which enables
the co-registration of PET/SPECT/CT images and the delineation of
regions of interest (ROIs) for quantiﬁcation of activity (PET/SPECT)
in speciﬁc organs. ROIs for diﬀerent organs were deﬁned in order to
express uptake in each organ as percentage of injected dose per gram
(%ID/mL). Image-based quantiﬁcation of the SPECT images was not
reliable due to the presence of the high-energy γ emissions of 89Zr that
introduced a high level of noise in the data.
Ex Vivo Biodistribution Studies. Biodistribution studies were
carried out in accordance with British Home Oﬃce regulations
governing animal experimentation. The mice from the imaging studies
were used for the biodistribution studies. Mice under anesthesia were
culled by cervical dislocation, and the organs of interest were dissected.
Each sample was weighed and counted with a γ counter (LKB
compugamma), together with standards prepared from a sample of the
injected material. If required, organs were weighted before freezing
using OCT (VWR, Lutterworth, UK). The percent of injected dose
per gram of tissue was calculated for each tissue type. The percent of
injected dose per gram of 89Zr-PLA in metastatic lung tissue was
obtained by calculating the average %ID and mass of nonmetastatic
lungs (from the 89Zr-PLA in non-tumor-bearing NSG mice study) and
subtracting these average values to each value from the 89Zr-PLA study
with tumor-bearing 3E.Δ.NT/NSG mice.
Fluorescence Microscopy of Tissues. Harvested tissues were
stored at −80 °C until most radioactivity was decayed and samples
were considered safe to handle without radioprotection. Subsequently,
10 μm thick tissue sections were cut using a cryostat and mounted on
superfrost slides (VWR, Lutterworth, UK). Sections were ﬁxed with
4% PFA for 15 min at room temperature, blocked with 1% (w/v) BSA
(30 min), and stained with Hoechst 33342 (1 μg/mL in PBS, 30 min)
and mounted in Mowiol containing 2.5% (v/v) Dabco. For staining
with anti-CD31, cut sections were treated with Fix & Perm Solution
B1000 (ADG, Kaumberg, Austria) and blocked with 1% (w/v) BSA.
Subsequently, samples were stained with the indicated primary
antibodies in blocking buﬀer for 2 h at room temperature before
being washed and incubated with appropriate ﬂuorophore-conjugated
secondary antibodies in blocking buﬀer for 45 min in the dark at room
temperature. Samples were then stained with Hoechst 33342 (1 μg/
mL in PBS, 15 min), washed, and mounted in Mowiol containing 2.5%
(w/v) Dabco as an antifade. Images were taken using a TCS SP5
(Leica, Wetzlar, Germany) confocal microscope equipped with Plan-
Neoﬂuor 25×/0.5 NA and Plan-Apochromat 63×/1.4 NA objectives.
Autoradiography of Tissues. Harvested tissues were cut into
∼25 μm thick sections using a cryostat and mounted on superfrost
slides (VWR, Lutterworth, UK). Sections were ﬁxed with 4% PFA for
15 min at room temperature, washed, mounted in Mowiol, and
exposed to a storage phosphor screen for either 2 min at 3 h post-
dissection to obtain the 99mTc signal or 20 min at 5 days post-
dissection to obtain the 89Zr signal. The storage phosphor screen was
read out using a Typhoon 9200 imager (Amersham Biosciences,
Amersham, UK) and analyzed using manufacturer’s Image Quant
software.
Human Absorbed Radiation Dosimetry Estimation. Human
absorbed radiation dose (Medical Internal Raditaion Dose (MIRD)
adult male and female standard models) was estimated using
OLINDA/EXM version 1.1 (Vanderbilt University, Nashville, TN,
USA)54 from the animal PET image-based time % injected dose curves
(non-decay-corrected) of the 3E.Δ.NT/NSG study with 89Zr-PLA.
Preclinical data in the form of percentage uptake per gram of tissue
were extrapolated to human percentage uptake per organ (standard
MIRD model organ weights), using the method originally proposed by
Kirschner et al.55 and subsequently applied by Chang et al.56 Organ
masses used to scale from mouse to man were obtained from the ex
vivo biodistribution experiment. The % injected dose values were
rescaled with tumor uptake (for both models) and uterus uptake (for
male only) excluded from the calculations.
Statistics. Student’s t-tests were used to calculate P values, and
unless otherwise indicated, Prism software (GraphPad, La Jolla, CA/
USA) was used. Numbers in the text indicate means of pooled data ±
standard deviation unless otherwise stated.
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